Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy-Reference-Cited by-同舟云学术

Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy

Published:2017-04-28 Issue:35 Volume:8 Page:58108-58121
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Fidler Mary Jo¹,Frankenberger Casey²,Seto Richard¹,Lobato Gabriela C.³,Fhied Cristina L.²,Sayidine Selina²,Basu Sanjib⁴,Pool Mark²,Karmali Reem⁵⁶,Batus Marta¹,Lie Wen-Rong⁷,Hayes David⁷,Mistry Jehangir⁷,Bonomi Philip¹,Borgia Jeffrey A.²³

Affiliation:

1. Section of Medical Oncology, Rush University Medical Center, Chicago, IL 60612, USA

2. Pathology, Rush University Medical Center, Chicago, IL 60612, USA

3. Biochemistry, Rush University Medical Center, Chicago, IL 60612, USA

4. Preventative Medicine, Rush University Medical Center, Chicago, IL 60612, USA

5. Hematology, Oncology and Cell Therapy at Rush University Medical Center, Chicago, IL 60612, USA

6. Present address: Division of Hematology and Oncology, Northwestern University, Chicago, IL 60612, USA

7. EMD Millipore Corporation, St. Charles, MO 63304, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation;Lung Cancer;2024-08

2. Prognostic Impact of Interleukin-8 Levels in Lung Cancer: A Meta-Analysis and a Bioinformatic Validation;2024

3. Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Myocardial Impairment by Speckle Tracking Echocardiography in Lung Cancer Patients;Frontiers in Cardiovascular Medicine;2022-01-28

4. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/−L1 directed immune checkpoint inhibition.;Journal of Immunological Methods;2021-03

5. SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery;Journal for ImmunoTherapy of Cancer;2020-12